Nelson Telles Garcia, MD
Cardiovascular Disease · Des Moines, IANPI 1922360726
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,301 of the $7,023 with a category attached, or 89.7%. 27 manufacturers reported payments, led by Boston Scientific at 27.4% of the total. Reporting peaked in 2021 at $1,443 and has fallen 65.0% since, to $505 in 2025.
Across 381 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Novartis$969
- Astellas Pharma US Inc$382
- Abbott$370
- Pfizer$289
- plus $2K from 21 others
What the payments were for
- Travel & lodging$3205%
- Food & beverage$6,30190%
- Education$4016%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 106 | $1,921 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 63 | $1,233 |
| Novartis | 77 | $969 |
| Astellas Pharma US Inc | 4 | $382 |
| Abbott | 22 | $370 |
| Pfizer | 13 | $289 |
| Johnson & Johnson | 19 | $258 |
| AstraZeneca | 8 | $245 |
| Boehringer Ingelheim | 10 | $230 |
| Amgen | 10 | $160 |
| E.r. Squibb & Sons, L.L.C. | 8 | $128 |
| Regeneron Healthcare Solutions, Inc. | 6 | $119 |
| Sanofi-aventis U.S. LLC | 5 | $96 |
| Alnylam Pharmaceuticals Inc. | 3 | $93 |
| Bayer | 5 | $92 |
| Amarin Pharma, Inc. | 5 | $87 |
| Lantheus Medical Imaging, Inc. | 3 | $59 |
| Medtronic(2 entities) | 2 | $51 |
| Merck | 3 | $46 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $36 |
| Scpharmaceuticals Inc. | 1 | $35 |
| Lundbeck LLC | 2 | $28 |
| Teleflex LLC | 1 | $24 |
| Novo Nordisk | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$636
- LifeVest$158
- WAINUA$123
- VYNDAQEL$108
How this compares
$7,023 in reported general payments places this provider in the 85th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 686 | $587,588 |
| VyndaqelTafamidis Meglumine | 23 | $508,594 |
| XareltoRivaroxaban | 268 | $256,657 |
| JardianceEmpagliflozin | 257 | $232,927 |
| EntrestoSacubitril/Valsartan | 219 | $186,754 |
| Repatha SureclickEvolocumab | 175 | $103,319 |
| FarxigaDapagliflozin Propanediol | 41 | $31,630 |
| BrilintaTicagrelor | 22 | $17,517 |
| Praluent PenAlirocumab | 23 | $11,977 |
| Repatha SyringeEvolocumab | 20 | $11,309 |
| Atorvastatin Calcium | 1,106 | $8,769 |
| Metoprolol Succinate | 739 | $7,760 |
| Ezetimibe | 254 | $6,285 |
| Rosuvastatin Calcium | 354 | $5,314 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 245 | $5,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndaqel | $289 | $1,096,182709 claims |
| Johnson & JohnsonXarelto | $258 | $256,657268 claims |
| Boehringer IngelheimJardiance | $230 | $232,927257 claims |
| NovartisEntresto | $969 | $186,754219 claims |
| AstraZenecaFarxiga, Brilinta | $245 | $49,14763 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 142 cardiovascular disease providers in Iowa.
Other cardiovascular disease in Des Moines
- Craig StarkDes Moines$28K
- Shubha Deep RoyDes Moines$9K
- Wafic ItaniDes Moines$5K
- Marc KleinDes Moines$5K
- Eduardo AntezanoDes Moines$4K
- Muhammad AwanDes Moines$4K
- Gardar SigurdssonDes Moines$2K
- Ratna GangiDes Moines$2K
- Deepika AbbadiDes Moines$2K
- Abdul ChughtaiDes Moines$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.